Skip to main content

The Delhi High Court granted an ex parte interim injunction restraining the defendants from marketing VARDENAFIL and VARDENAFIL HYDROCHLORIDE in India.

The court noted that the defendants product contained the plaintiff Bayer’s patented pharmaceutical preparation, but without its permission to exploit the same. The defendants’ drugs, though not commercially launched in India, were being exported to other countries.

Bayer initiated legal proceedings in India upon learning that drugs infringing its patent, valid till 2018, had been seized by customs authorities in Latvia.

Bayer Intellectual Property GmbH v Vipro Lifescience and anr.

Most Recent

News & Insights

VIEW ALL
News & Updates, Thought Leadership
May 19, 2026

First published by Asialaw. Authors: Prachi Agarwal and Medha Singh Introduction: Copyright law, particularly in the domain of literary works, grapples

Copyright in Literary Works: When themes converge but expressions diverge
News & Updates, Thought Leadership
May 08, 2026

First published by Asialaw. Authors: Safir Anand and Ritu Bhargava India’s online gaming sector has entered a decisive new phase. With the Government’s

A New Era for Digital Play: India’s Online Gaming Regulator Comes into Force
News & Updates, Thought Leadership
May 06, 2026

First published by Lexology. Authors: Safir Anand and Rashi Chandhoke In recent years, the intellectual property (IP) ecosystem has undergone a significant

India Waives IP Filing Fees for Sports Sector
Thought Leadership
Apr 30, 2026

First published by SpicyIP. By: Lakshmidevi Somanath India’s trademark register is quietly bleeding value. Each year, marks with real commercial recall

Dead Marks, Live Assets – The Case for a Registry Supervised Auction of Lapsed Trademarks in India